|
TW202021956A
|
|
Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
|
|
CA3051419A1
|
|
Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
|
|
WO2020036574A1
|
|
Activators of the retinoic acid inducible gene "rig-i' pathway and methods of use thereof
|
|
AU2015271915A1
|
|
Anti-viral compounds
|
|
TW201625573A
|
|
CHROMENONE anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
WO2016057518A1
|
|
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
CN106456615A
|
|
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
WO2015009812A2
|
|
Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
|
|
US2014199348A1
|
|
Anti-viral compounds
|
|
NZ622636A
|
|
Substituted benzothiazole compounds and their use in the treatment of viral infections
|
|
MX2014003889A
|
|
Anti-viral compounds.
|
|
CN103491965A
|
|
Method and cells for identifying rig-i pathway regulators
|
|
TW201202231A
|
|
Anti-viral compounds
|
|
US2013039887A1
|
|
Methods of Identifying and Using Anti-Viral Compounds
|
|
WO2011133727A2
|
|
Anti-viral compounds
|
|
US2013035397A1
|
|
Anti-Viral Compounds
|
|
EP2560636A2
|
|
Anti-viral compounds
|
|
EP2560635A2
|
|
Anti-viral compounds
|
|
AU2011242683A1
|
|
Anti-viral compounds
|
|
CA2798209A1
|
|
Anti-viral compounds
|
